Our bodies already have soldiers that kill foreign cells — they're called T-cells. The trouble is, cancer cells are clever enough to "raise a hand and tell the soldiers we're on the same side," hitting the brakes so they don't get attacked. The class of drugs called checkpoint inhibitors does one thing — release that brake, and let the body's own soldiers go to work. This chapter is the story of how that simple idea became Keytruda, the best-selling drug in the world (~$31.7B a year), why 2028 is the deadline the whole industry is watching, and who's lining up to take the throne.
Contains
Theme index· base 100 · USD total return
Why is Immuno-Oncology / Checkpoint moving?
Latest
▲2▼2
Checkpoint class expands into new cancers, but Keytruda's subcutaneous setback and biosimilar threat bite
▲
Checkpoint drugs win new approvals in colon and kidney cancer Roche's Tecentriq became the first approved adjuvant immunotherapy for stage III dMMR colon cancer, cutting recurrence risk by 50%. Merck's WELIREG plus LENVIMA won FDA approval for advanced kidney cancer after prior checkpoint therapy. These expand the class into new patient groups and earlier treatment settings, supporting long-term demand.
New regulatory wins show the checkpoint class still growing into new indications, a core positive force for the theme.
Dutch court blocks subcutaneous Keytruda in eight European markets A Dutch patent court ruled that Merck's subcutaneous Keytruda infringes Halozyme's delivery patent, ordering a halt to sales in eight European countries. The intravenous version remains available, but the ruling blocks a key convenience formulation that was meant to defend Keytruda's franchise ahead of biosimilar competition.
This is a new legal setback that directly limits a major checkpoint drug's reach in Europe, a negative force for the theme.
Bispecific antibodies show strong Phase 3 results in lymphoma and ovarian cancer AbbVie and Genmab's epcoritamab plus R-CHOP cut progression risk by 51% in newly diagnosed DLBCL, the first Phase 3 win for a bispecific combo in frontline lymphoma. Agenus reported 48% three-year survival for its dual checkpoint combo in recurrent ovarian cancer. These advance next-generation immuno-oncology approaches.
New clinical data validate bispecific and dual-checkpoint strategies, a positive technology force for the theme.
Pembrolizumab biosimilar distribution deal in Europe signals coming price pressure Orion Pharma signed an exclusive European distribution deal with Qilu Pharma for an intravenous pembrolizumab biosimilar. While not yet approved, this prepares the market for cheaper copies of Keytruda, threatening the pricing power of the checkpoint class as Merck's key patent expires in 2028.
This is a new concrete step toward biosimilar competition that will pressure checkpoint drug pricing, a negative force.
Baili Tianheng's Yizekang Combined with Radiotherapy for Head and Neck Squamous Cell Carcinoma Receives Clinical Trial Approval
Baili Tianheng announced that the company recently received a Drug Clinical Trial Approval Notice issued by the National Medical Products Administration. The clinical trial of its self-developed, world-first bispecific antibody drug conjugate Yizekang, also known as luncoitab, in combination with radiotherapy for locally advanced unresectable head and neck squamous cell carcinoma and other solid tumors has been approved. To date, the drug has initiated more than 45 clinical trials in China and the United States, including 20 Phase III clinical studies, and 9 indications have been included in the breakthrough therapy designation list by the Center for Drug Evaluation.
Biotech & Genomic Medicine › Oncology Therapeutics ▲Regulation
Biotech & Genomic Medicine › Antibody-Drug Conjugates (ADC) ▲Regulation
Biotech & Genomic Medicine › Immuno-Oncology / Checkpoint ▲Regulation
688506.CG · Regulation · Positive Baili Tianheng received NMPA clinical trial approval for Yizekang combined with radiotherapy in head and neck squamous cell carcinoma.
Akeso Doses First Patient in Phase III Perioperative Cadonilimab Colon Cancer Study
Akeso, Inc. announced that the first patient has been dosed in a Phase III clinical study evaluating cadonilimab, its first-in-class PD-1/CTLA-4 bispecific antibody, as monotherapy in the neoadjuvant/adjuvant perioperative treatment of resectable microsatellite instability-high or mismatch repair-deficient colon cancer. The trial, designated COMPASSION-40/AK104-313, marks a significant new indication for cadonilimab beyond gastric, lung, and cervical cancers, and is the 13th Phase III or registrational study of the therapy conducted globally. Colorectal cancer is among the malignancies with the highest incidence and mortality worldwide, and patients with MSI-H/dMMR colon cancer derive limited benefit from conventional perioperative chemotherapy, with pathological response rates of only approximately 7%. No immunotherapy has yet been approved anywhere for the perioperative treatment of localized MSI-H/dMMR colon cancer. Supporting evidence comes from a prior Phase II study of cadonilimab monotherapy as neoadjuvant treatment in MSI-H/dMMR colorectal cancer, where data presented at the 2024 ESMO Immuno-Oncology Congress showed a pathological complete response rate of 84.6% and a major pathological response rate of 100% among patients who proceeded to surgery, with a manageable safety profile.
Biotech & Genomic Medicine › Oncology Therapeutics ▲Technology
Biotech & Genomic Medicine › Immuno-Oncology / Checkpoint ▲Technology
9926.HK · Technology · Positive First patient dosed in Phase III trial of cadonilimab for perioperative MSI-H/dMMR colon cancer, a new indication with strong prior Phase II response data.
FDA Approves Roche's Tecentriq for Stage III dMMR Colon Cancer
The FDA has approved Tecentriq and Tecentriq Hybreza, in combination with fluoropyrimidine and oxaliplatin chemotherapy, for the adjuvant treatment of stage III deficient DNA mismatch repair colon cancer, marking the 12th U.S. indication for Roche's cancer immunotherapy. The decision was based on the phase III ATOMIC study, which enrolled 712 patients with stage III dMMR colon cancer and showed that adding Tecentriq reduced the risk of disease recurrence or death by 50% compared with chemotherapy alone, with a 36-month disease-free survival rate of 86% versus 76% for chemotherapy alone. The approval makes Tecentriq the first approved adjuvant immunotherapy regimen for stage III dMMR colon cancer, and Roche plans additional regulatory filings including a submission to the European Medicines Agency. Tecentriq generated sales of CHF 1.7 billion in the first half of 2026, up 6%. Roche shares have risen 3.5% year to date.
Biotech & Genomic Medicine › Oncology Therapeutics ▲Regulation
Biotech & Genomic Medicine › Immuno-Oncology / Checkpoint ▲Regulation
ROP.SW · Regulation · Positive FDA approves Tecentriq as first adjuvant immunotherapy for stage III dMMR colon cancer, expanding Roche's label and sales potential.
Merck Wins FDA Approval for WELIREG Plus LENVIMA in Kidney Cancer
Merck received FDA approval for WELIREG plus LENVIMA in adults with advanced renal cell carcinoma following prior PD-1/PD-L1 therapy. The approved regimen combines WELIREG at 120 mg once daily with LENVIMA at 20 mg once daily. Separately, Merck began a first-in-human Phase I trial using Cyprumed's oral peptide delivery platform for an undisclosed peptide candidate. The approval expands Merck's oncology portfolio beyond Keytruda, while the Cyprumed trial carries execution risk for the company's newer oral peptide technology.
Dutch Court Blocks Merck's Keytruda SC in Eight European Markets
A Dutch patent court has ruled in favor of Halozyme Therapeutics, finding that Merck's subcutaneous formulation of Keytruda infringes one of Halozyme's MDASE patents covering technology used to deliver drugs through subcutaneous injection. The ruling orders Merck to stop manufacturing and selling Keytruda SC in Belgium, Denmark, France, Ireland, Italy, Sweden, Switzerland and the Netherlands, and bars Merck from letting its affiliates continue selling the drug in those markets, including through its European marketing authorization. The order does not affect the intravenous version of Keytruda, which remains available to patients because it is not covered by Halozyme's patent or the injunction. It marks the second legal victory for Halozyme over Keytruda SC, following a December 2025 German preliminary injunction that stopped Merck from distributing or offering the drug in Germany, and Halozyme has also filed a separate U.S. patent infringement lawsuit alleging that Keytruda SC, marketed as Keytruda Qlex, infringes 15 of its MDASE patents. Merck said it strongly disagrees with the Dutch decision, considers Halozyme's patent invalid globally and the infringement allegation without merit, and is evaluating its next steps. The ruling is a setback for Merck as it seeks to expand Keytruda's use ahead of the loss of U.S. patent protection for the original formulation, with biosimilar competition potentially beginning in December 2028; the IV and SC versions together generate nearly half of Merck's topline. Halozyme said the MDASE technology in the Merck dispute is separate from its ENHANZE technology and licensing program, which is a major source of royalty revenue and has been used in 10 commercialized products across more than 100 markets, including Johnson & Johnson's Darzalex and argenx's Vyvgart. Halozyme shares have surged 65% year to date compared with the industry's 1% growth.
Biotech & Genomic Medicine › Oncology Therapeutics ▼Competition
Biotech & Genomic Medicine › Immuno-Oncology / Checkpoint ▼Competition
HALO · Regulation · Positive Dutch patent court ruled in Halozyme's favor, blocking Merck's Keytruda SC in eight European markets over its MDASE patent.
MRK · Regulation · Negative Injunction bars Merck from making and selling Keytruda SC in eight European markets, a setback to expanding the drug ahead of patent loss.
Pfizer Oncology Sales Seen Rising on Padcev, Lorbrena Ahead of Q3 Results
Pfizer is expected to report higher oncology sales in the third quarter of 2026, driven by key drugs Padcev, Lorbrena and the Braftovi-Mektovi combination, which should offset declining sales of Ibrance and Adcetris. Oncology comprises around 27% of Pfizer's total revenues, and in the second quarter of 2026 oncology revenues increased 3% to $4.17 billion, with 2% operational growth. The Zacks Consensus Estimate for Padcev is $692 million, while that for Ibrance is $1.01 billion. Pfizer, which markets six cancer biosimilars, is also expected to provide updates on key oncology candidates on its third-quarter conference call, including atirmociclib, sasanlimab and sigvotatug vedotin, as well as PF-08634404, a dual PD-1/VEGF inhibitor in-licensed from Chinese biotech 3SBio in 2025 for which Pfizer has initiated nine studies, including two pivotal phase III trials. Pfizer will announce its third-quarter results on Nov. 3.
Biotech & Genomic Medicine › Oncology Therapeutics ▲Demand
Biotech & Genomic Medicine › Antibody-Drug Conjugates (ADC) ▲Demand
Biotech & Genomic Medicine › Immuno-Oncology / Checkpoint ▲Demand
PFE · Demand · Positive Expected higher oncology sales in Q3 driven by Padcev, Lorbrena and Braftovi-Mektovi offsetting declines in Ibrance and Adcetris.
1530.HK · Demand · Positive Pfizer in-licensed PF-08634404 from 3SBio and has initiated nine studies including two pivotal phase III trials, implying milestone/royalty potential for 3SBio.
Biohaven Signs Regeneron Supply Deal for BHV-1530 Cancer Combination
Biohaven Ltd. announced a clinical supply agreement with Regeneron Pharmaceuticals in September 2026 to test BHV-1530 in combination with cemiplimab, sold as Libtayo, in patients with solid tumors. The BHV-1530 collaboration follows earlier monotherapy and preclinical data suggesting potential synergy with Anti-PD-1 therapy, and it builds on an existing supply agreement covering Biohaven's next-generation TROP2-directed ADC BHV-1510, deepening Regeneron's involvement across Biohaven's oncology pipeline. The company has no revenue yet, carries very large ongoing losses, and depends on future trial readouts and capital markets rather than cash flow. Near-term swing factors include upcoming data from opakalim in focal epilepsy, the MoDE autoimmune programs, and obesity results from taldefgrobep, with regulatory progress on troriluzole also in focus. Investors in the Simply Wall St Community hold only two fair value views on Biohaven, spanning from about US$21 to nearly US$70 per share.
Biotech & Genomic Medicine › Oncology Therapeutics ▲Supply
Biotech & Genomic Medicine › Immuno-Oncology / Checkpoint ▲Supply
Biotech & Genomic Medicine › Antibody-Drug Conjugates (ADC) ▲Supply
BHVN · Demand · Positive Biohaven signed a clinical supply agreement with Regeneron to test BHV-1530 in combination with cemiplimab, advancing its oncology pipeline.
REGN · Demand · Positive Regeneron will supply cemiplimab (Libtayo) for the combination trial, deepening its involvement across Biohaven's oncology pipeline.
Dutch Court Blocks Merck's Subcutaneous Keytruda in Eight European Markets
A Dutch court ruled in favor of Halozyme Therapeutics in late September 2026, issuing an injunction that halts manufacture and sale of Merck's subcutaneous Keytruda across eight European countries following a patent dispute. The decision affects one of Merck's key immuno-oncology formulations in important European markets, though it leaves the central near-term catalyst around late-stage oncology and cardiometabolic launches unchanged. Separately, Merck secured a new global license for SciBrunch's preclinical KRAS G12D inhibitor SPR2015, a deal carrying a US$400 million upfront charge that will weigh on reported earnings in the near term. Merck's narrative projects $75.3 billion in revenue and $22.5 billion in earnings by 2029, requiring 4.2% yearly revenue growth and a $19.3 billion earnings increase from $3.2 billion today, with a $155.68 fair value implying 10% upside. Some of the most optimistic analysts model roughly US$82.1 billion in revenue and US$30.2 billion in earnings by 2029, weighting pipeline breadth and AI-enabled efficiency more heavily than access risks such as the subcutaneous Keytruda ruling.
Biotech & Genomic Medicine › Immuno-Oncology / Checkpoint ▼Regulation
Biotech & Genomic Medicine › Oncology Therapeutics ▼Regulation
HALO · Regulation · Positive Dutch court injunction in Halozyme's favor halts Merck's subcutaneous Keytruda across eight European markets, a legal win for Halozyme.
MRK · Regulation · Negative Injunction blocks manufacture and sale of subcutaneous Keytruda in eight European markets following the patent dispute.
MRK · Capital · Negative Separate SciBrunch KRAS G12D license carries a US$400 million upfront charge that will weigh on near-term reported earnings.
Tempus Expands Multi-Year Collaboration with Moderna and Merck for Intismeran Autogene
Tempus announced an expanded, multi-year collaboration with Moderna and Merck to support the potential commercialization of intismeran autogene, also known as V940 or mRNA-4157, a potential first-in-class individualized neoantigen therapy being evaluated in combination with KEYTRUDA in patients with completely resected stage IIB-IV melanoma and other cancer types. Intismeran autogene is jointly developed by Moderna and Merck, known as MSD outside the United States and Canada, and the new collaboration builds on joint efforts initiated last year. Under the agreement, Tempus will manage the timely collection and transfer of tumor tissue and blood samples required for next-generation sequencing, and, subject to applicable regulatory approvals, will also provide NGS services to support the intismeran autogene design and manufacturing process. Financial terms of the collaboration were not disclosed. Moderna Chief Business Officer Said Francis said the partnership lets the company leverage Tempus's commercial footprint and advanced sequencing capabilities, while Jannie Oosthuizen, President of Global Oncology and MSD International, said such collaborations are helping build the infrastructure needed to bring individualized neoantigen therapies to patients at scale.
Biotech & Genomic Medicine › mRNA Platforms ▲Supply
Biotech & Genomic Medicine › Oncology Therapeutics ▲Supply
Biotech & Genomic Medicine › RNA Therapeutics ▲Supply
Biotech & Genomic Medicine › Diagnostics & Precision Testing ▲Supply
Biotech & Genomic Medicine › Immuno-Oncology / Checkpoint ▲Supply
TEM · Demand · Positive Tempus wins an expanded multi-year collaboration to provide tissue/blood collection and NGS services for intismeran autogene.
MRK · Demand · Positive Expanded collaboration supports commercialization of intismeran autogene, which Merck co-develops with Moderna and evaluates with KEYTRUDA.
MRNA · Demand · Positive Moderna's jointly developed intismeran autogene gains Tempus support for sample collection, NGS design, and manufacturing toward commercialization.
AstraZeneca Opens US$1b R&D Center in Kendall Square
AstraZeneca has opened a new US$1b global research and development center in Kendall Square, Massachusetts, consolidating its US work in oncology, cell therapy, chronic and rare diseases, and obesity into a single expanded hub. The site uses robotics and AI-enabled automation to support the company's research programs and broader drug development efforts. AstraZeneca is a GB-based biopharmaceutical group with a £185.5 billion market cap that spends heavily on discovering and developing prescription medicines. The company said the center tightens the link between early science and late-stage assets, which could affect how quickly it refines drug candidates and retires weaker programs. Investors will be watching for Phase II or Phase III readouts in obesity, COPD and key oncology programs over 2027 to 2029 as markers of whether the build-out is translating into a more resilient portfolio mix.
Biotech & Genomic Medicine › Oncology Therapeutics Capital
Biotech & Genomic Medicine › Metabolic, Diabetes & Obesity Capital
Biotech & Genomic Medicine › Immuno-Oncology / Checkpoint Capital
Biotech & Genomic Medicine › Cell Therapy (CAR-T & beyond) Capital
AZN.LSE · Technology · Positive AstraZeneca opened a $1B R&D center using robotics and AI to speed drug discovery and refine candidates across oncology, cell therapy, and obesity.
Genmab Reports Phase 3 Win for Epcoritamab and Phase 1/2 Data for Rina S
Genmab posted two fresh oncology trial readouts, including a Phase 3 win for epcoritamab in newly diagnosed diffuse large B cell lymphoma. The EPCORE DLBCL 2 trial, run with AbbVie, reported that epcoritamab plus R CHOP cut the risk of disease progression or death by 51% versus R CHOP alone in patients with higher risk DLBCL. Separately, the Phase 1/2 RAINFOL 01 study of rinatabartsesutecan, or Rina S, in platinum resistant ovarian cancer reported a 45.9% confirmed objective response rate in a heavily pretreated population, with a median duration of response of 12.1 months and no clear safety signals around eye toxicity, peripheral neuropathy, interstitial lung disease or stomatitis. The trial headlines arrive after a strong run in the shares, with the DKK2,482.0 price coming alongside a 31.18% 90 day share price return and a 23.67% year to date share price return, while the 5 year total shareholder return is down 8.75%.
Genmab Shares Jump 10.7% on Positive Phase III EPCORE DLBCL-2 Data
Genmab A/S Sponsored ADR shares rallied 10.7% in the last trading session to close at $38.48, following positive top-line results from the phase III EPCORE DLBCL-2 study. Genmab and its partner AbbVie announced that epcoritamab in combination with R-CHOP demonstrated a statistically significant improvement in progression-free survival in patients with newly diagnosed diffuse large B-cell lymphoma. The company is expected to post quarterly earnings of $0.37 per share in its upcoming report, a year-over-year change of -43.1%, on revenues of $1.18 billion, up 15.7% from the year-ago quarter. The consensus EPS estimate for the quarter has been revised 8.7% higher over the last 30 days, and the stock currently carries a Zacks Rank #3 (Hold).
Orion Pharma signs European distribution deal with Qilu Pharma Europe for pembrolizumab biosimilar
Orion Corporation, known as Orion Pharma, has entered into an agreement with Qilu Pharma Europe to commercialise an intravenous pembrolizumab biosimilar in Europe. Under the terms, Orion Pharma gains the exclusive right to distribute, market and sell Qilu's IV pembrolizumab biosimilar across Europe, while Qilu will supply the product and receive a share of profits plus certain development, regulatory and sales milestone payments. Pembrolizumab is an immune checkpoint inhibitor used to treat various cancers, and Qilu is currently developing the IV version. Satu Ahomäki, EVP Generics and Consumer Health at Orion Pharma, said the deal expands the company's strategic partnership with Qilu and brings its division closer to its long-term targets and strategic goals. Orion Pharma reported net sales of EUR 1,890 million in 2025 and employs about 4,000 professionals worldwide.
Biotech & Genomic Medicine › Biosimilars ▲Competition
Biotech & Genomic Medicine › Immuno-Oncology / Checkpoint ▲Competition
Biotech & Genomic Medicine › Oncology Therapeutics ▲Competition
0M2N.LSE · Demand · Positive Orion gains exclusive European rights to distribute, market and sell Qilu's IV pembrolizumab biosimilar, expanding its product portfolio and sales reach.
0M2O.LSE · Demand · Positive Orion B shares benefit from the same exclusive European distribution deal for Qilu's pembrolizumab biosimilar.
271560.KO · Demand · Positive Orion Corp is the parent entity behind Orion Pharma, which secured exclusive European commercialization rights for the pembrolizumab biosimilar.
Qilu Pharma Europe · Demand · Positive Qilu Pharma Europe secures a European commercialization partner and will receive profit share plus development, regulatory and sales milestones for its pembrolizumab biosimilar.
Summit Therapeutics, AstraZeneca and Daiichi Sankyo to Study Ivonescimab Plus Datroway Combos
Summit Therapeutics has signed a clinical collaboration with AstraZeneca and its Japan-based partner Daiichi Sankyo to evaluate ivonescimab in combination with the antibody-drug conjugate Datroway, also known as datopotamab deruxtecan, across multiple solid tumors including breast and lung cancers. The collaboration is expected to initially focus on a phase III study in first-line triple-negative breast cancer, expanding ivonescimab's development into a new tumor type. Under the agreement, each company will supply its respective drug, AstraZeneca or Daiichi will sponsor the planned studies, and the companies will share study costs while retaining development and commercial rights to their own therapies. The Datroway collaboration builds on the larger deal between AstraZeneca and Summit announced in the last week, under which AstraZeneca agreed to invest $2 billion in Summit to accelerate development of ivonescimab, with the companies also set to evaluate ivonescimab alongside AstraZeneca's investigational Claudin-18.2-targeted ADC sonesitatug vedotin, or Sone-Ve, in gastrointestinal cancers. An FDA filing is under review seeking approval for ivonescimab plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who had progressed following EGFR-TKI treatment, with a final decision expected by Nov. 14, 2026.
Biotech & Genomic Medicine › Oncology Therapeutics ▲Capital
Biotech & Genomic Medicine › Immuno-Oncology / Checkpoint ▲Capital
Biotech & Genomic Medicine › Antibody-Drug Conjugates (ADC) ▲Capital
4568.JP · Technology · Positive Daiichi Sankyo's Datroway (datopotamab deruxtecan) will be evaluated in combination with ivonescimab across multiple solid tumors, including a phase III triple-negative breast cancer study
AZN.LSE · Technology · Positive AstraZeneca will co-sponsor and supply its Datroway ADC in a new phase III combination study with ivonescimab, expanding its oncology pipeline
AstraZeneca Closes $2 Billion Equity Investment in Summit Therapeutics
Summit Therapeutics announced the closing of AstraZeneca's $2.0 billion strategic equity investment in the company. Under the Securities Purchase Agreement, AstraZeneca purchased approximately 108,955 shares of preferred stock convertible into Summit common stock at a 1:1,000 ratio, representing a common stock price of $18.36, a premium over the closing trading price on the day the investment was announced. The proceeds will support accelerated development of ivonescimab, a potential first-in-class investigational PD-1 / VEGF bispecific antibody, across solid tumor settings including combinations with antibody drug conjugates such as sonesitatug vedotin and Datroway. Summit Chairman and Co-Chief Executive Officer Robert W. Duggan said the investment reflects AstraZeneca's confidence in Summit and in ivonescimab's potential to redefine cancer treatment. Baker Hostetler LLP is serving as legal advisor to Summit.
Biotech & Genomic Medicine › Oncology Therapeutics ▲Capital
Biotech & Genomic Medicine › Immuno-Oncology / Checkpoint ▲Capital
Biotech & Genomic Medicine › Antibody-Drug Conjugates (ADC) ▲Capital
AZN.LSE · Capital · Positive AstraZeneca closed a $2.0 billion strategic equity investment in Summit Therapeutics, a major financing/M&A event for AstraZeneca.
Alligator Bioscience Names CFO Johan Giléus as CEO, Søren Bregenholt to Step Down at Year-End
Alligator Bioscience has appointed Johan Giléus, currently CFO, as its new Chief Executive Officer effective 1 January 2027, with Søren Bregenholt remaining CEO until 31 December 2026 to ensure a seamless transition. Giléus will combine the CEO and CFO roles, reflecting the company's strategic refocusing towards its financial interest in the HER2-targeting antibody programme HLX22, as announced on 23 July 2026. Following the transition, Alligator will operate with a minimal organisation, supported by the Board of Directors and external consultants. Chairman Hans-Peter Ostler thanked Bregenholt for five years of leadership through a demanding period for the biotech sector, noting that the outcome with mitazalimab did not meet expectations, and said Giléus knows Alligator and its financial interest in HLX22 in depth. Giléus has more than 30 years of senior experience, including the last nine years in the Swedish biotech industry, and joined Alligator as CFO in August 2024 after leaving Deloitte Sweden's partnership in 2015. Alligator, listed on Nasdaq Stockholm under ATORX and headquartered in Lund, Sweden, has discontinued further internal development of mitazalimab and is seeking to out-license or divest the asset.
Biotech & Genomic Medicine › Oncology Therapeutics ▼Capital
Biotech & Genomic Medicine › Immuno-Oncology / Checkpoint ▼Capital
Alligator Bioscience AB · Capital · Negative CEO transition to a minimal organisation after discontinuing mitazalimab development and refocusing on the HLX22 financial interest signals a strategic retreat
Agenus Reports 48% Three-Year Survival for BOT+BAL in Recurrent Ovarian Cancer
Agenus Inc. announced three-year follow-up results from the ovarian cancer cohort of its 400+ patient Phase 1b C-800-01 trial, showing an estimated 48% three-year overall survival for botensilimab plus balstilimab in recurrent ovarian cancer. The estimate was unchanged from two years, with median overall survival of 14.8 months, a 23% objective response rate among 35 evaluable patients, and a median duration of response of 9.7 months. At last follow-up, 25% of the 44 patients who received at least one dose, 11 in total, were alive and off all therapy. The heavily pretreated population had received a median of four prior lines of therapy, 77% had received bevacizumab and 57% a PARP inhibitor, and nearly three-quarters had platinum-resistant or refractory disease; estimated three-year survival was 47% in that subgroup and 61% in the 17 patients whose disease had progressed on a PARP inhibitor. The data were presented by Rebecca L. Porter of Dana-Farber Cancer Institute at the 2026 International Gynecologic Cancer Society Annual Global Meeting in Montréal, and Agenus said no new safety signals or treatment-related deaths were reported.
Biotech & Genomic Medicine › Oncology Therapeutics ▲Technology
Biotech & Genomic Medicine › Immuno-Oncology / Checkpoint ▲Technology
AGEN · Technology · Positive Agenus reported positive three-year follow-up data for botensilimab plus balstilimab in recurrent ovarian cancer, with 48% three-year overall survival and no new safety signals.
J&J Innovative Medicine Set for Q3 Growth Led by Oncology
Johnson & Johnson is scheduled to report its third-quarter 2026 results on Oct. 13, with investors focused on sales performance in its Innovative Medicine segment. The segment has posted five consecutive quarters of sales above $15 billion despite the loss of exclusivity of Stelara, and J&J expects continued above-market growth driven by Darzalex, Erleada, Carvykti, Tecvayli and Rybrevant/Lazcluze in oncology, Tremfya and other immunology products, and Spravato and Caplyta in neuroscience. Newer launches are expected to contribute more than in the second quarter, with Inlexzo sales more than doubling sequentially from around $30 million in the first quarter, while investors will watch for initial sales of the newly launched plaque psoriasis pill Icotyde and Imaavy, approved in the United States in August for a second indication, warm autoimmune hemolytic anemia. Stelara's loss of exclusivity cut the segment's growth by 760 basis points in the second quarter, and the negative impact is expected to be steeper in the third quarter, with biosimilar competition from Amgen, Teva Pharmaceutical Industries and Samsung Bioepis/Sandoz, along with declining Imbruvica sales and European biosimilars for Simponi and a U.S. generic version of Opsumit, weighing on results. Overall, Innovative Medicine is expected to have been J&J's principal growth engine in the quarter, with oncology providing the strongest contribution and Tremfya helping offset Stelara's biosimilar-driven decline.
Biotech & Genomic Medicine › Oncology Therapeutics ▲Competition
Biotech & Genomic Medicine › Autoimmune & Immunology Therapeutics ▼Competition
Biotech & Genomic Medicine › Biosimilars ▲Competition
Biotech & Genomic Medicine › Immuno-Oncology / Checkpoint Competition
JNJ · Competition · Negative Stelara's loss of exclusivity with biosimilar competition from Amgen, Teva and Samsung Bioepis/Sandoz, plus declining Imbruvica and generic/biosimilar pressure on Simponi and Opsumit, weighs on segment results.
JNJ · Demand · Positive J&J expects above-market Innovative Medicine growth led by oncology drugs Darzalex, Erleada, Carvykti, Tecvayli and Rybrevant/Lazcluze, plus newer launches like Inlexzo and Icotyde.
TEVA · Competition · Negative Teva's Stelara biosimilar competition is cited as weighing on J&J's Innovative Medicine results.
Yuanta turns bullish on SINOBIO as it partners with STADA to bring cancer drug TQB3570 to Europe, sets target at 7.10 baht per DR
Yuanta Securities issued an analysis turning more bullish on SINOBIO19, or the ordinary shares of SINO BIOPHARMACEUTICAL LIMITED (1177.HK), after the company announced a partnership with STADA, a global pharmaceutical company in Germany, to bring TQB3570, a biologic drug with efficacy close to that of Keytruda, the world's most popular cancer treatment, into the European, UK, and Swiss markets, with the potential to expand into the US market in the future. Under the deal, Sino Bio will manufacture and supply the drug itself but distribute it under STADA's brand, and will recognize a profit share of more than 10%. This means Sino Bio will recognize revenue from both manufacturing and an additional share of profits when STADA sells the drug in the region, creating a new revenue base for the company. Meanwhile, the Chinese government continues to target innovative pharmaceuticals as one of its key industries and will push for the sector to grow by an average of 20% per year during 2026-2030, giving the company the opportunity to receive government support both in speeding up approvals for drugs in its pipeline and in supporting R&D. As for this year's normalized profit outlook, the Bloomberg Consensus expects normalized profit to continue growing by 5%. The current price trades at a 2027 PER of 18 times. It gives a target price of 7.10 baht per DR, implying 44% upside.
Biotech & Genomic Medicine › Oncology Therapeutics ▲Demand
Biotech & Genomic Medicine › Immuno-Oncology / Checkpoint ▲Demand
Biotech & Genomic Medicine › Biosimilars Demand
1177.HK · Demand · Positive Partnership with STADA to bring cancer drug TQB3570 to Europe/UK/Switzerland, with Sino Bio manufacturing and earning >10% profit share, creates a new revenue base.
1177.HK · Regulation · Positive Chinese government targets innovative pharmaceuticals as a key industry, supporting faster approvals and R&D for Sino Bio's pipeline.
STADA Arzneimittel AG · Demand · Neutral STADA is the named European distribution partner for TQB3570, but the article gives no detail on financial impact for STADA itself.
Regeneron Falls 4% as Sanofi Alliance Expands Without Better Dupixent Terms
Regeneron shares fell 4% after the biotech company expanded its immunology alliance with Sanofi on terms that left the economics of its blockbuster drug Dupixent untouched. Under the deal, Sanofi will pay Regeneron $1 billion upfront and up to $7 billion in development, regulatory, and commercial milestones for four next-generation, long-acting antibodies, with the two drugmakers splitting global development costs, commercialization expenses, and future profits equally. The agreement settles prior litigation but leaves the existing Dupixent profit-sharing terms unchanged, disappointing investors who had hoped a renegotiation would yield better economics on the franchise; nearly a quarter of investors surveyed by RBC Capital sought more constructive terms, according to Investing.com. Sanofi shares rose roughly 2% in European trading, according to Reuters, while Regeneron reversed an early morning gain, later trading at $736.56, down 2.9% from the previous close. Regeneron is down 5.1% since the start of the year and trades 13.6% below its 52-week high of $852.03.
Biotech & Genomic Medicine › Autoimmune & Immunology Therapeutics Capital
Biotech & Genomic Medicine › Immuno-Oncology / Checkpoint Capital
REGN · Capital · Negative Expanded Sanofi alliance leaves Dupixent profit-sharing terms unchanged, disappointing investors who hoped for better economics on the franchise.
SAN.PA · Capital · Positive Sanofi pays $1B upfront and up to $7B in milestones for four next-gen antibodies while splitting costs and profits equally, and its shares rose ~2%.
Raymond James Adds Xencor, Calyxt, UnitedHealth to October Healthcare Top Picks
Raymond James has updated its Healthcare Top Picks list for October, adding Xencor, Calyxt, and UnitedHealth Group while removing Relay Therapeutics, Tyra Biosciences, and Oscar Health. Xencor replaces Relay Therapeutics, with the firm anticipating significant interest in Xencor's dataset at ESMO at the end of October and seeing near-term upside on a positive readout and a clear path to pivotal development for XmAb819 in clear cell renal cell carcinoma, even as it maintains a Strong Buy rating on Relay Therapeutics. Calyxt replaces Tyra Biosciences, with Raymond James citing an increasingly derisked setup for both of Calyxt's lead assets, CLYM116 and budoprutug; initial Phase 2 data for CLYM116 is expected next year ahead of a Phase 3 study in IgAN patients, while additional budoprutug data across pMN, ITP, and SLE is due in the fourth quarter of 2026, and the firm noted the subcutaneous formulation could differentiate it from approved anti-CD19 Uplizna. UnitedHealth Group replaces Oscar Health ahead of third-quarter earnings in mid-October, with the firm saying the recent pullback on Stars and midterm election-related concerns creates an attractive setup into what it expects to be a strong quarter. Raymond James said it remains positive on Oscar Health with an Outperform rating but currently prefers UnitedHealth given the monthly nature of the list.
Biotech & Genomic Medicine › Oncology Therapeutics ▲Capital
Biotech & Genomic Medicine › Immuno-Oncology / Checkpoint Capital
UNH · Capital · Positive Added to Raymond James' Healthcare Top Picks ahead of Q3 earnings, with the recent Stars-related pullback seen as an attractive setup.
XNCR · Capital · Positive Added to Raymond James' Healthcare Top Picks on anticipated ESMO dataset interest and near-term upside from an XmAb819 readout.
OSCR · Capital · Neutral Raymond James remains positive with an Outperform rating but removed Oscar Health from the Top Picks list in favor of UnitedHealth.
RLAY · Capital · Neutral Removed from the Top Picks list, though Raymond James maintains its Strong Buy rating on Relay Therapeutics.
TYRA · Capital · Neutral Removed from the Top Picks list as Calyxt replaces Tyra Biosciences; no company-specific development cited.
Moderna Falls 6% After Citigroup Downgrade to Sell
Moderna shares fell 6% in the morning session after Citigroup downgraded the biotechnology company to Sell from Neutral, warning that a 222% rally had pushed its valuation to unsustainable levels. Analyst Meacham wrote in a note to clients that the stock's surge since mid-August's Phase 3 INTerpath-001 melanoma readout reflects aggressive sales forecasts and unrealistic probability-of-success assumptions, according to Tipranks. Reaching a near-$200 share price would require roughly $13 billion in annual oncology revenue attributable to Moderna, nearly seven times Citigroup's model, a hurdle Meacham characterized as unrealistic. The run-up expanded Moderna's market capitalization to roughly $80 billion, rivaling Regeneron despite materially lower expected revenue and earnings, and Meacham added that even under a theoretical 100% probability of success across lead cancer programs, Citigroup's pipeline valuation model justifies only about $100 per share. Moderna is up 520% since the beginning of the year and at $191.35 per share is trading close to its 52-week high of $203.46 from September 2026.
AstraZeneca Wins FDA Priority Review for IMFINZI in Bladder Cancer
AstraZeneca said the FDA has granted Priority Review to a supplemental Biologics License Application for IMFINZI with enfortumab vedotin in muscle-invasive bladder cancer. The application targets patients who are ineligible for or decline cisplatin-based chemotherapy, a group with limited treatment choices. Priority Review shortens the FDA review timeline for this regimen, reflecting the agency's view that it may offer a meaningful clinical advance. AstraZeneca, a £192.8 billion pharmaceuticals group focused on prescription medicines, has been building its oncology presence across several tumour types, so any potential label expansion for IMFINZI touches a core therapy area rather than a side project for the business.
Biotech & Genomic Medicine › Oncology Therapeutics ▲Regulation
Biotech & Genomic Medicine › Immuno-Oncology / Checkpoint ▲Regulation
Biotech & Genomic Medicine › Antibody-Drug Conjugates (ADC) ▲Regulation
AZN.LSE · Regulation · Positive FDA granted Priority Review to AstraZeneca's IMFINZI/enfortumab vedotin application for muscle-invasive bladder cancer, a regulatory milestone that could expand the label.
AstraZeneca Files FDA New Drug Application for ORPATHYS and TAGRISSO in Advanced Lung Cancer
AstraZeneca has filed a New Drug Application with the US FDA for combining ORPATHYS and TAGRISSO in a specific form of advanced non small cell lung cancer after EGFR TKI treatment. The filing comes as the company's shares have fallen 10.29% over 90 days and 8.56% year to date, though the 1 year total shareholder return of 13.04% and 5 year total shareholder return of 55.73% remain positive. The most followed analyst narrative puts fair value at £159.11 against a last close of £124.28, implying 22% undervaluation, with 206 investors backing that view. Management estimates its late-stage pipeline across oncology, rare diseases, and cardiovascular and metabolic therapies could generate $10+ billion in peak risk-adjusted revenue. Risks to the rerating include tighter drug pricing regimes in key markets and heavier pressure on blockbuster franchises as competition builds.
Biotech & Genomic Medicine › Oncology Therapeutics ▲Regulation
Biotech & Genomic Medicine › Antibody-Drug Conjugates (ADC) ▲Regulation
Biotech & Genomic Medicine › Immuno-Oncology / Checkpoint Regulation
AZN.LSE · Regulation · Positive AstraZeneca filed an FDA New Drug Application for the ORPATHYS plus TAGRISSO combination in advanced EGFR TKI-treated NSCLC, a regulatory milestone advancing its oncology pipeline.
AstraZeneca to Invest $2 Billion in Summit; CanSino Biologics Hits 20-Cent Daily Limit Up
On September 29, Summit announced that AstraZeneca will make a strategic equity investment of $2 billion in the company and will take the lead in advancing clinical research on ivonescimab combined with AstraZeneca's Sonesitatug Vedotin for the treatment of multiple gastrointestinal tumors. The two parties also plan to further promote clinical exploration of combination therapies involving ivonescimab and a range of AstraZeneca antibody-drug conjugates and other anti-tumor drugs. Boosted by this news, innovative drug concept stocks were repeatedly active in early trading on September 30. CanSino Biologics hit the 20-cent daily limit up, Berry Genomics hit the daily limit up, and Sino Biological, Tri-Prime Gene, and Walvax Biotechnology quickly followed with gains. On the same day, China's three major A-share indices opened collectively higher. As of press time, the Shanghai Composite Index rose 0.35 percent, the Shenzhen Component Index rose 0.48 percent, the ChiNext Index rose 0.92 percent, and the SSE STAR 50 Composite Index rose 0.31 percent. By sector, biotechnology, power generation equipment, and gas were relatively active, while the real estate sector led declines, and internet, semiconductor, and software sectors fluctuated in adjustment.
Biotech & Genomic Medicine › Oncology Therapeutics ▲Capital
Biotech & Genomic Medicine › Immuno-Oncology / Checkpoint ▲Capital
Biotech & Genomic Medicine › Antibody-Drug Conjugates (ADC) ▲Capital
AZN.LSE · Capital · Positive AstraZeneca will make a $2 billion strategic equity investment in Summit and lead clinical research on ivonescimab combinations.
Summit Hosting LLC · Capital · Positive Summit announced AstraZeneca's $2 billion strategic equity investment and a lead role in advancing ivonescimab combination clinical research.
688185.CG · Demand · Positive CanSino Biologics hit the 20-cent daily limit up as part of the innovative drug concept rally sparked by AstraZeneca's Summit investment, but no company-specific development is cited.
AstraZeneca to Invest $2 Billion in Summit Therapeutics for Cancer Drug Combinations
AstraZeneca agreed to invest $2 billion in Summit Therapeutics to test new cancer drug combinations, a stake that would give the biopharmaceutical company rights equivalent to roughly 12% of Summit's outstanding common shares. The companies plan to test AstraZeneca's sonesitatug vedotin alongside Summit's ivonescimab in gastrointestinal cancers, with each retaining the rights to its own medicine and room to pursue a broader clinical program if the partnership delivers. AstraZeneca shares were down about 0.7% at $164.95 at 9.55am EST on Tuesday. At that price, AstraZeneca trades 9.24% below its $181.75 GF Value estimate.
Biotech & Genomic Medicine › Oncology Therapeutics ▲Capital
Biotech & Genomic Medicine › Antibody-Drug Conjugates (ADC) ▲Capital
Biotech & Genomic Medicine › Immuno-Oncology / Checkpoint Capital
AZN.LSE · Capital · Positive AstraZeneca is investing $2 billion in Summit Therapeutics for cancer drug combination trials, gaining rights to roughly 12% of Summit's shares.
AstraZeneca Invests $2 Billion in Summit; FICO Sinks on FHFA Mortgage Pricing Change
AstraZeneca agreed to make a $2 billion strategic equity investment in Summit Therapeutics, sending the biopharmaceutical company's shares up 17.1% in premarket trading. The investment supports a collaboration combining Summit's flagship bispecific antibody, ivonescimab, with AstraZeneca's oncology pipeline, and AstraZeneca will acquire convertible preferred shares at a price equivalent to $18.36 per common share, a 10% premium to Summit's five-day volume-weighted average price. Fair Isaac tumbled 15% after the Federal Housing Finance Agency announced changes to mortgage pricing that will introduce competition to FICO's longstanding role in the mortgage credit-scoring market; FHFA Director Bill Pulte said Fannie Mae and Freddie Mac will consolidate their separate pricing matrices into a single unified grid that will incorporate VantageScore alongside the traditional FICO Classic score. CarMax rose 3.7% after reporting fiscal second-quarter earnings of $1.16 per share, beating analyst expectations of 68 cents, with revenue of $7.88 billion topping forecasts of about $7.06 billion. AAR Corp. surged 6.9% after announcing an agreement to acquire a 65% controlling interest in MRO Holdings at an implied enterprise value of $4 billion, alongside adjusted diluted EPS of $1.49 and revenue of $918 million that beat expectations. Netflix rose 1.4% after Deutsche Bank upgraded the streaming giant to Buy from Hold with a $95 price target, while AbCellera Biologics gained 2.1% on a JPMorgan Overweight initiation with a $17 price target and Q32 Bio rose 9.4% ahead of a key clinical data presentation at the European Academy of Dermatology and Venereology Congress in Vienna beginning Sept. 30.
Biotech & Genomic Medicine › Oncology Therapeutics ▲Capital
Biotech & Genomic Medicine › Immuno-Oncology / Checkpoint ▲Capital
AIR · Capital · Positive AAR agreed to acquire a 65% controlling interest in MRO Holdings at a $4 billion enterprise value, alongside EPS and revenue beats.
AZN.LSE · Capital · Positive AstraZeneca agreed to a $2 billion strategic equity investment in Summit Therapeutics and a collaboration combining ivonescimab with its oncology pipeline.
FICO · Regulation · Negative FHFA's mortgage pricing change will add VantageScore competition to FICO's longstanding role in mortgage credit scoring.
KMX · Capital · Positive CarMax reported fiscal Q2 EPS of $1.16 and revenue of $7.88 billion, beating analyst expectations.
NFLX · Capital · Positive Deutsche Bank upgraded Netflix to Buy from Hold with a $95 price target.
QTTB · Technology · Positive Q32 Bio rose ahead of a key clinical data presentation at the EADV Congress, a product/R&D catalyst.
AstraZeneca invests $2bn in Summit Therapeutics for cancer drug tie-up
AstraZeneca has invested two billion US dollars, or £1.5 billion, in US pharmaceutical firm Summit Therapeutics as part of a cancer treatment research joint venture. The equity investment will help speed up development of Summit's experimental drug ivonescimab, which targets specific proteins to attack cancer cells and stop them growing. The two firms will collaborate on the medicine and research how it could be combined with AstraZeneca's treatments, particularly its sonesitatug vedotin drug, with trials in gastrointestinal cancer to begin imminently. Each company will contribute its respective medicine for the planned combination trials and jointly fund trial costs, while retaining development and commercial rights to its own medicines. Summit's shares soared by nearly a fifth after markets closed overnight in New York, while AstraZeneca's shares were 2% higher on Tuesday morning in London.
Biotech & Genomic Medicine › Oncology Therapeutics ▲Capital
Biotech & Genomic Medicine › Antibody-Drug Conjugates (ADC) ▲Technology
Biotech & Genomic Medicine › Immuno-Oncology / Checkpoint Competition
AZN.LSE · Capital · Positive AstraZeneca invests $2bn in Summit Therapeutics and forms a cancer drug joint venture, a major capital/M&A commitment.
AZN.LSE · Technology · Positive The tie-up advances combination trials of Summit's ivonescimab with AstraZeneca's sonesitatug vedotin in gastrointestinal cancer.
China's innovative drug industry has welcomed another major licensing deal. Shanghai Sprout and Merck jointly announced a global exclusive licensing agreement for SPR2015, a preclinical oral KRAS G12D (ON) inhibitor, with a potential total value of $2.13 billion, including an upfront payment of $400 million, with the remainder tied to development and commercialization milestones. Meanwhile, Summit Therapeutics, the overseas partner of Akeso, announced that AstraZeneca will make a $2 billion strategic equity investment in Summit and intends to lead clinical exploration of Akeso's first-in-class tumor immunotherapy 2.0 cornerstone drug ivonescimab in combination with AstraZeneca's Sonesitatug Vedotin for treating multiple gastrointestinal tumors. The two parties also signed a memorandum of understanding to further advance clinical exploration of ivonescimab combined with a range of AstraZeneca antibody-drug conjugates and other anti-tumor drugs. Boosted by the news, as of 10:01 a.m. on September 29, 2026, the STAR Market Biotech ETF managed by Penghua Fund, with ticker 588250, saw its underlying index, the SSE STAR Market Biomedical Index with code 000683, rise 1.10%. Among constituents, InventisBio rose 5.16%, Micro-Tech Nanjing rose 3.84%, Hotgen Biotech rose 3.13%, and Huiyu Pharmaceutical and Yound Biotechnology followed the gains. China Securities pointed out that the medical device sector has reached an inflection point in 2026, and stocks with improving performance are expected to see dual recovery in valuation and earnings. High-value consumables and in-vitro diagnostics segments are expected to gradually clear the impact of centralized procurement price cuts in the second half of the year, and leaders in niche tracks will accelerate growth.
Biotech & Genomic Medicine › Oncology Therapeutics ▲Capital
Biotech & Genomic Medicine › Immuno-Oncology / Checkpoint ▲Capital
Biotech & Genomic Medicine › Antibody-Drug Conjugates (ADC) ▲Capital
上海思璞锐 · Capital · Positive Shanghai Sprout is the licensor of SPR2015, receiving $400M upfront and up to $2.13B in a global exclusive deal with Merck.
MRK · Capital · Positive Merck signs a global exclusive licensing deal for SPR2015 KRAS G12D inhibitor worth up to $2.13B, expanding its oncology pipeline.
9926.HK · Capital · Positive Akeso's partner Summit gets a $2B AstraZeneca equity investment and AZ will lead clinical exploration of Akeso's ivonescimab in combination therapies.
AZN.LSE · Capital · Positive AstraZeneca makes a $2B strategic equity investment in Summit and signs an MOU to advance ivonescimab combinations with its ADCs.
AstraZeneca Submits US NDA for ORPATHYS plus TAGRISSO in MET-Driven EGFR-Mutated Lung Cancer
AstraZeneca has submitted a New Drug Application to the US Food and Drug Administration for ORPATHYS, or savolitinib, plus TAGRISSO, or osimertinib, for patients with locally advanced or metastatic non-small cell lung cancer whose tumors have MET overexpression or amplification and who progressed on or after an EGFR tyrosine kinase inhibitor therapy, HUTCHMED announced. The filing is supported by the global SAFFRON Phase III trial, the first global Phase III trial to demonstrate statistically significant and clinically meaningful improvements in progression-free survival and overall survival in this setting, versus doublet platinum-based chemotherapy in patients who progressed on TAGRISSO. SAFFRON enrolled 338 patients across 230 centers in 29 countries and builds on evidence from the SACHI Phase III and SAVANNAH Phase II trials, with results to be presented in a Presidential Symposium at the upcoming European Society for Medical Oncology Congress 2026. ORPATHYS is jointly developed by AstraZeneca and HUTCHMED and is commercialized by AstraZeneca; the combination is already approved in China based on SACHI and received a temporary authorization in Switzerland based on SAVANNAH. Johnny Cheng, Acting Chief Executive Officer and Chief Financial Officer of HUTCHMED, said the filing is an important step toward potentially bringing the biomarker-directed, chemotherapy-free oral combination to patients in the US.
Biotech & Genomic Medicine › Oncology Therapeutics ▲Demand
Biotech & Genomic Medicine › Immuno-Oncology / Checkpoint ▲Demand
0013.HK · Regulation · Positive HUTCHMED announced the US NDA submission for ORPATHYS plus TAGRISSO, advancing its jointly developed drug toward US approval.
AZN.LSE · Regulation · Positive AstraZeneca submitted the US NDA for ORPATHYS plus TAGRISSO, a combination it commercializes, based on positive SAFFRON Phase III data.
Merck's Remigromig Hits Phase 2b/3 Endpoint in Diabetic Macular Edema
Merck & Co., Inc. announced positive topline results from its pivotal Phase 2b/3 BRUNELLO trial of remigromig, a potentially first-in-class tri-specific Wnt pathway agonist, in adults with diabetic macular edema. At 52 weeks, both the 0.5 mg and 0.8 mg doses met the primary endpoint by demonstrating non-inferiority to the standard-of-care active control, 0.5 mg ranibizumab, for mean change in best-corrected visual acuity. While remigromig was generally well tolerated, higher rates of proliferative diabetic retinopathy, vitreous hemorrhage, and adverse event-related discontinuations were observed in the treatment arms. Full year-one data will be presented at the American Academy of Ophthalmology Annual Meeting on October 10. The company reported $16.6 billion in Q2 worldwide sales, up 5%, with KEYTRUDA and KEYTRUDA QLEX accounting for $8.4 billion, or over 50%, of that total, and full-year 2026 non-GAAP EPS expectations were revised to $2.66–$2.76 due to $3.62 per share in one-time charges following the Terns and Cidara transactions.
Biotech & Genomic Medicine › Oncology Therapeutics Competition
Biotech & Genomic Medicine › Immuno-Oncology / Checkpoint Competition
Biotech & Genomic Medicine › Metabolic, Diabetes & Obesity Technology
MRK · Technology · Positive Remigromig met the primary endpoint in the pivotal Phase 2b/3 BRUNELLO trial for diabetic macular edema, a positive R&D readout.
MRK · Capital · Neutral Q2 sales rose 5% to $16.6B but full-year 2026 non-GAAP EPS guidance was cut to $2.66–$2.76 due to $3.62/share in one-time charges from the Terns and Cidara deals.
FDA Expands Merck's Welireg Label to Third Kidney Cancer Indication
Merck announced that the FDA has expanded the label of its oral cancer drug Welireg, also known as belzutifan, for a third indication in advanced renal cell carcinoma, the most common type of adult kidney cancer. The drug is now approved in combination with Eisai's Lenvima, or lenvatinib, to treat adult patients with advanced renal cell carcinoma with a clear cell component following a PD-1/PD-L1 inhibitor. The approval is supported by data from the phase III LITESPARK-011 study, which evaluated the combination against Exelixis' Cabometyx, or cabozantinib, and met one of its dual primary endpoints of progression-free survival, reducing the risk of disease progression or death by 26 percent, though it did not meet the other primary endpoint of overall survival and showed only a trend toward improvement. The new indication could further expand Welireg's addressable patient population in advanced clear cell renal cell carcinoma, and it gives Merck another treatment option in a market where Cabometyx is established. Welireg sales reached 470 million dollars in the first half of 2026, up 57 percent year over year, and the drug is already approved for two other clear cell renal cell carcinoma indications as well as for von Hippel-Lindau disease and for pheochromocytoma or paraganglioma in patients aged 12 years and older.
Biotech & Genomic Medicine › Oncology Therapeutics ▲Regulation
Biotech & Genomic Medicine › Immuno-Oncology / Checkpoint ▲Regulation
MRK · Regulation · Positive FDA expanded Welireg's label to a third kidney cancer indication, broadening its addressable patient population.
EXEL · Competition · Negative Welireg/Lenvima combo beat Cabometyx on progression-free survival, threatening Exelixis's established kidney cancer drug.
4523.JP · Regulation · Positive Welireg is now approved in combination with Eisai's Lenvima for advanced renal cell carcinoma, expanding Lenvima's use.
Akeso Enrolls First Patient in Global Phase III Cadonilimab Gastric Cancer Trial
Akeso, Inc. announced that the first patient has been enrolled in COMPASSION-37 (AK104-311), a global, multicenter Phase III head-to-head trial evaluating cadonilimab, its first-in-class PD-1/CTLA-4 bispecific antibody, plus chemotherapy versus chemotherapy with or without nivolumab as first-line treatment for HER2-negative, previously untreated, unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma. The study is co-led by Dr. Yelena Y. Janjigian of Memorial Sloan Kettering Cancer Center, Professor Markus Möhler of Johannes Gutenberg University Mainz, Professor Jiafu Ji of Peking University Cancer Hospital & Institute, and Professor Lin Shen of Peking University Cancer Hospital. It follows the Chinese Phase III COMPASSION-15 study, which enrolled 610 patients with a notably high proportion of low PD-L1 expression at 49.8% and PD-L1-negative disease at 23%, and showed that cadonilimab plus chemotherapy significantly reduced the risk of death in the overall population regardless of PD-L1 expression status. Akeso said the trial aims to test whether dual PD-1/CTLA-4 immune checkpoint blockade can improve outcomes beyond the current standard of care, particularly for patients with low PD-L1 expression, a population for which effective immunotherapy options remain a significant global unmet need. Cadonilimab is currently approved in China for first-line gastric cancer, first-line cervical cancer, and recurrent or metastatic cervical cancer, and is being evaluated in more than 13 registrational or Phase III trials globally, two of them international multicenter studies.
Biotech & Genomic Medicine › Immuno-Oncology / Checkpoint Competition
Biotech & Genomic Medicine › Oncology Therapeutics Competition
9926.HK · Technology · Positive First patient enrolled in global Phase III head-to-head trial of cadonilimab, advancing its bispecific antibody toward broader international registrational use.
Innovent Expands Phase 3 MarsLight-11 Trial of IBI363/TAK-928 to Non-Squamous NSCLC
Innovent Biologics announced the expansion of the global Phase 3 MarsLight-11 trial of IBI363, also known as TAK-928, to include patients with non-squamous non-small cell lung cancer. The trial previously evaluated the therapy only in patients with squamous NSCLC whose disease had progressed on or after chemotherapy and immunotherapy. The non-squamous evaluation will run as a new substudy, so MarsLight-11 will now comprise two independent substudies, one in squamous NSCLC and one in non-squamous NSCLC, each testing IBI363 monotherapy against docetaxel in unresectable, locally advanced or metastatic disease that has progressed during or after platinum-based chemotherapy and anti-PD-1/PD-L1 immunotherapy. IBI363/TAK-928 is a potential first-in-class alpha-biased IL-2/PD-1 bispecific fusion protein co-developed globally by Innovent and Takeda, and it has received two Fast Track Designations from the U.S. FDA and three Breakthrough Therapy Designations from China NMPA. In October 2025 the two companies signed a license and collaboration agreement covering global co-development and U.S. co-commercialization, with Takeda holding exclusive commercialization rights worldwide outside the U.S. and greater China.
Moderna and Merck's Melanoma Vaccine Meets Phase 3 Endpoint
Moderna and Merck reported that their Phase 3 INTerpath-001 trial of personalized cancer vaccine intismeran autogene plus Keytruda met its primary endpoint in melanoma, with full data presented earlier this month at the European Society for Medical Oncology Congress 2026. Moderna is also in talks with Middle East partners about potential investment and manufacturing cooperation, pairing its mRNA oncology push with efforts to extend its geographic footprint and industrial capabilities beyond its original COVID-19 franchise. The company recently won FDA approval of mFlusiva, its mRNA flu vaccine for adults 50 and older, underscoring its push to build a non-seasonal respiratory portfolio. Moderna's narrative projects $4.5 billion revenue and $782.2 million earnings by 2029, yielding a $119.56 fair value, a 40% downside to its current price, while some of the most optimistic analysts assume revenue could reach about US$8.5 billion and earnings turn positive by 2029.
Biotech & Genomic Medicine › mRNA Platforms ▲Technology
Biotech & Genomic Medicine › Immuno-Oncology / Checkpoint ▲Demand
Biotech & Genomic Medicine › Vaccines (Recombinant & Traditional) ▲Regulation
Biotech & Genomic Medicine › Oncology Therapeutics ▲Technology
MRNA · Technology · Positive Moderna's personalized cancer vaccine intismeran autogene met the Phase 3 primary endpoint in melanoma, validating its mRNA oncology platform.
MRNA · Regulation · Positive Moderna recently won FDA approval of mFlusiva, its mRNA flu vaccine for adults 50 and older, expanding its non-seasonal respiratory portfolio.
MRNA · Capital · Neutral Moderna is in talks with Middle East partners about potential investment and manufacturing cooperation.
MRK · Technology · Positive Merck's Keytruda combined with Moderna's intismeran autogene met the Phase 3 primary endpoint in melanoma, a positive clinical readout for its oncology franchise.
BioNTech Wins Health Canada Approval for XFG-Adapted COMIRNATY as Gotistobart Nearly Doubles Survival in Phase 3 Lung Cancer Trial
Pfizer Canada and BioNTech announced Health Canada's approval of the Omicron XFG-adapted COMIRNATY vaccine for individuals aged 6 months and older, aligning with 2026-2027 public health recommendations. A few days earlier, BioNTech and OncoC4 reported that the investigational CTLA-4 antibody gotistobart nearly doubled median overall survival versus chemotherapy in a Phase 3 lung cancer trial stage. The Health Canada authorization, following earlier US and EU XFG approvals in 2026, shows the COVID-19 franchise still contributes regulated, seasonal revenue while BioNTech leans into oncology. BioNTech's narrative projects €2.2 billion revenue and €390.1 million earnings by 2029, implying a 6.0% yearly revenue decline and an earnings increase of about €2.1 billion from -€1.7 billion today, with a $118.06 fair value and 20% upside to its current price. Bullish analysts assume revenue climbs to about €3.0 billion and earnings to €313.1 million by 2029, though the new gotistobart data and oncology execution risks could shift how those upbeat assumptions are weighed against more cautious views.
AnaptysBio Posts US$183.88 Million Quarterly Profit on Tax Benefit After First Tracks Spin-Off
AnaptysBio reported fourth-quarter and six-month 2026 net income of US$183.88 million and US$131 million respectively, with basic earnings per share from continuing operations of US$6.06 for the quarter and US$6.09 for the six months. The bulk of that quarterly profit came from a US$181.5 million income-tax benefit tied to the release of a deferred-tax valuation allowance following the separation of First Tracks Biotherapeutics, an accounting change that lifts reported earnings without delivering equivalent cash. The company's investment case now rests on its royalty-focused model around Jemperli and imsidolimab, with near-term catalysts seen in royalty performance, litigation outcomes with GSK and management's use of a US$100 million buyback rather than the tax boost itself. Three Simply Wall St community valuations for AnaptysBio range from about US$88.50 to US$1,276.20 per share, underscoring how widely individual views on the stock diverge.
Biotech & Genomic Medicine › Immuno-Oncology / Checkpoint Pricing
ANAB · Capital · Neutral Q4 profit of US$183.88M driven mostly by a US$181.5M deferred-tax valuation-allowance release after the First Tracks spin-off, an accounting gain without equivalent cash.
TRAX · Capital · Neutral Its separation from AnaptysBio triggered the deferred-tax valuation-allowance release; no standalone news about First Tracks itself.
Bristol Myers Squibb announced the first presentation of results from the pivotal Phase 3 EXCALIBER-RRMM trial showing that ZENBEXUS, or iberdomide, in combination with daratumumab and dexamethasone doubled minimal residual disease-negative complete response rates compared with daratumumab, bortezomib and dexamethasone, at 41.1% versus 20.7%. The data, presented at the 23rd Annual Meeting of the International Myeloma Society in Glasgow and simultaneously published in The Lancet Oncology, covered 420 evaluable patients at a median follow-up of 15.7 months and showed a statistically significant improvement with an odds ratio of 2.75. Overall response rate was 88.9% with the ZENBEXUS-based triplet versus 76.1% for the comparator, while complete response or better nearly doubled at 45.9% versus 24.9%. Based on these results, ZENBEXUS in combination with daratumumab and hyaluronidase-fihj and dexamethasone received accelerated approval from the U.S. Food and Drug Administration on August 13 for adult patients with multiple myeloma who have received at least one prior line of therapy including a proteasome inhibitor and an immunomodulatory agent, marking the arrival of a new treatment class. Evaluation of the dual primary endpoint of progression-free survival in the confirmatory analysis cohort of 800 patients is ongoing.
Biotech & Genomic Medicine › Oncology Therapeutics ▲Technology
Biotech & Genomic Medicine › Immuno-Oncology / Checkpoint Competition
BMY · Technology · Positive ZENBEXUS (iberdomide) triplet doubled MRD-negative complete response rates in Phase 3 EXCALIBER-RRMM and received FDA accelerated approval, a positive R&D/clinical development for BMS.
J&J's RYBREVANT Regimen Hits 34.3-Month Median Survival in PAPILLON Lung Cancer Trial
Johnson & Johnson's RYBREVANT plus chemotherapy delivered a median overall survival of 34.3 months in the final overall-survival analysis of the Phase 3 PAPILLON study, versus 27.9 months for chemotherapy alone, in patients with advanced non-small cell lung cancer carrying EGFR exon 20 insertion mutations. J&J described the result as the longest reported median overall survival in this patient population, where historical median overall survival has ranged from approximately 16 to 24 months and historical five-year survival has been reported at just 8%. The protocol-specified final overall-survival analysis produced a hazard ratio of 0.87, a 95% confidence interval of 0.66 to 1.14, and a P-value of 0.307, meaning it did not reach statistical significance, a result complicated by crossover, as 76% of eligible patients in the chemotherapy arm crossed over to second-line RYBREVANT after disease progression. A prespecified analysis accounting for that crossover showed a 43% reduction in the risk of death with first-line RYBREVANT plus chemotherapy, with a hazard ratio of 0.57, while progression-free survival through second disease progression reached 28.3 months with the RYBREVANT combination versus 17.5 months with chemotherapy. J&J reported no new safety signals with longer follow-up, though the most common treatment-related adverse events occurring in at least 30% of patients included paronychia and neutropenia, each at 60%, and rash at 58%.
Biotech & Genomic Medicine › Oncology Therapeutics ▲Demand
Biotech & Genomic Medicine › Immuno-Oncology / Checkpoint Competition
JNJ · Technology · Positive RYBREVANT plus chemo showed 34.3-month median overall survival in the Phase 3 PAPILLON EGFR exon 20 insertion NSCLC trial, the longest reported in this population
AstraZeneca's SERENA-4 Trial Misses Primary Endpoint in Advanced Breast Cancer
AstraZeneca announced on September 11, 2026, that its Phase III SERENA-4 trial of Etcamah, also known as camizestrant, combined with palbociclib failed to meet its primary endpoint of progression-free survival in patients with upfront first-line ER-positive, HER2-negative advanced breast cancer. The regimen showed numerical improvement over standard anastrozole plus palbociclib but did not reach statistical significance. The miss closes off a major first-line market expansion for camizestrant, capping its reach as a broad upfront replacement for standard aromatase inhibitors and shifting commercial dependence onto biomarker-defined niches such as ESR1-mutated patients, where the positive SERENA-6 trial established its role. AstraZeneca retains momentum through its existing oncology blockbusters and a late-stage pipeline that includes the ongoing Phase III CAMBRIA trials in early breast cancer. The company's investment case now hinges on converting specialized pipeline assets into approved targeted therapies while managing clinical execution risk and a sizable debt load.
Biotech & Genomic Medicine › Oncology Therapeutics ▼Demand
Biotech & Genomic Medicine › Immuno-Oncology / Checkpoint Competition
AZN.LSE · Technology · Negative Phase III SERENA-4 trial of camizestrant plus palbociclib missed its primary progression-free survival endpoint, closing off a major first-line market expansion.
